TNGX insider transactions
Tango Therapeutics Inc. (TNGX) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
TNGX insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Tango Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Adam CrystalPresident, R&D, since February 2023-$6.65M
- Jessica NewcombPrincipal Accounting Officer, since April 2026-$356K
- Robert AzelbyDirector, since June 2026
- Daniella BeckmanChief Financial Officer, since August 2021-$199K
- John B KetchumDirector, since August 2023
- Lesley Ann CalhounDirector, since August 2021
- Mace RothenbergDirector, since August 2021+$74K
- Sung LeeDirector, since January 2026
- Matthew GallChief Financial Officer, since April 2026
- Barbara WeberDirector, Executive Chair, since August 2021-$547K
- Malte PetersPresident & CEO, Director, since August 2021
- Third Rock Ventures IV, L.P.10% owner, since August 2021-$51.9M
- Alexis BorisyDirector, since August 2021
- Douglas BarryGeneral Counsel, since October 2021-$51.3K
- EcoR1 Capital, LLC10% owner, since October 2023-$8.44M
- Boxer Capital Management, LLCInsider, since October 2024-$20.1M
- Aaron I. DavisInsider
- MVA Investors, LLCInsider-$4.62M
- Boxer Capital, LLCInsider, since August 2021+$21.6M-$2.24M
- Third Rock Ventures VI, L.P.Director, since August 2023
- Reid M HuberDirector, since August 2021
- Alan HuangOfficer, since August 2021
- Aaron WeitzmanOfficer, since December 2022
- Braslyn Ltd.10% owner, since August 2021
- Tango Therapeutics, Inc.Director, since December 2021
- Marc RudoltzOfficer, since October 2021
- BCTG Holdings, LLC10% owner, since August 2021
Recent Form 3, 4, and 5 filings for TNGX
- President, R&D Crystal Adam exercised 5,000 shares at a strike of $2.91 and sold $112,108 worth of shares (5,000 units at $22.42) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Principal Accounting Officer Newcomb Jessica sold $157,661 worth of shares (7,031 units at $22.42) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 52,090 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam sold $660,796 worth of shares (27,000 units at $24.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Principal Accounting Officer Newcomb Jessica sold $198,613 worth of shares (8,200 units at $24.22) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 59,121 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $603,909 worth of shares (27,000 units at $22.37) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $735,517 worth of shares (27,000 units at $27.24) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam sold $798,908 worth of shares (27,000 units at $29.59) as part of a pre-agreed trading plan and exercised 27,000 shares at a strike of $5.20 (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Azelby Robert was granted 5,740 shares (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 3 filed by new insider Azelby Robert3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Ketchum John B was granted 4,000 shares, increasing direct ownership by 19% to 24,937 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Calhoun Lesley Ann was granted 4,000 shares, increasing direct ownership by 32% to 16,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Rothenberg Mace was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Lee Sung was granted 570 shares, increasing direct ownership by 3% to 22,870 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $617,571 worth of shares (27,000 units at $22.87) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam exercised 27,000 shares at a strike of $5.20 and sold $573,097 worth of shares (27,000 units at $21.23) as part of a pre-agreed trading plan (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Financial Officer Gall Matthew was granted 40,000 shares (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Lee Sung was granted 12,300 shares, increasing direct ownership by 123% to 22,300 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 3 filed by new insider Gall Matthew3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- New insider Newcomb Jessica claimed ownership of 67,321 shares (SEC Form 3)3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 4 filed by Crystal Adam4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam sold $303,765 worth of shares (20,251 units at $15.00), decreasing direct ownership by 15% to 112,622 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam sold $694,208 worth of shares (54,345 units at $12.77), decreasing direct ownership by 29% to 132,873 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Financial Officer Beckman Daniella sold $126,531 worth of shares (10,317 units at $12.26) and was granted 44,330 shares, increasing direct ownership by 23% to 184,297 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director, Executive Chair Weber Barbara was granted 37,522 shares and sold $374,294 worth of shares (30,519 units at $12.26), increasing direct ownership by 0.43% to 1,629,254 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President, R&D Crystal Adam was granted 47,460 shares and sold $226,300 worth of shares (18,452 units at $12.26), increasing direct ownership by 18% to 187,218 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- President & CEO Peters Malte was granted 350,000 shares, increasing direct ownership by 2,000% to 367,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Lee Sung was granted 10,000 shares (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 3 filed by new insider Lee Sung3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 4 filed by Director Peters Malte4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $4,846,575 worth of shares (477,401 units at $10.15) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $4,008,500 worth of shares (500,000 units at $8.02) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $2,559,329 worth of shares (363,541 units at $7.04) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $5,108,970 worth of shares (729,365 units at $7.00) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $2,115,358 worth of shares (302,194 units at $7.00) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $7,712,760 worth of shares (1,100,000 units at $7.01) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Peters Malte was granted 6,250 shares, increasing direct ownership by 56% to 17,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Calhoun Lesley Ann was granted 6,250 shares, increasing direct ownership by 100% to 12,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Rothenberg Mace was granted 6,250 shares, increasing direct ownership by 20% to 37,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Ketchum John B was granted 6,250 shares, increasing direct ownership by 43% to 20,937 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Borisy Alexis was granted 6,250 shares, increasing direct ownership by 56% to 17,500 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- General Counsel Barry Douglas sold $16,369 worth of shares (5,330 units at $3.07), decreasing direct ownership by 7% to 66,014 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Financial Officer Beckman Daniella sold $25,282 worth of shares (8,232 units at $3.07), decreasing direct ownership by 5% to 150,284 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Officer Crystal Adam sold $43,866 worth of shares (14,283 units at $3.07), decreasing direct ownership by 8% to 158,210 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Executive Officer Weber Barbara sold $57,710 worth of shares (18,791 units at $3.07), decreasing direct ownership by 1% to 1,622,251 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Financial Officer Beckman Daniella was granted 26,119 shares, increasing direct ownership by 20% to 158,516 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Officer Crystal Adam was granted 53,015 shares, increasing direct ownership by 44% to 172,493 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Chief Executive Officer Weber Barbara was granted 105,875 shares, increasing direct ownership by 7% to 1,641,042 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- General Counsel Barry Douglas was granted 27,363 shares, increasing direct ownership by 62% to 71,344 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Ecor1 Capital, Llc sold $8,435,743 worth of shares (2,700,000 units at $3.12) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Boxer Capital Management, Llc sold $9,671,200 worth of shares (3,080,000 units at $3.14) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Boxer Capital Management, Llc sold $4,348,710 worth of shares (633,000 units at $6.87), decreasing direct ownership by 9% to 6,690,642 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Boxer Capital Management, Llc sold $6,101,250 worth of shares (875,000 units at $6.97), decreasing direct ownership by 11% to 7,323,642 units (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- New insider Boxer Capital Management, Llc claimed ownership of 8,198,642 shares (SEC Form 3)3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $709,756 worth of shares (67,400 units at $10.53) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $867,135 worth of shares (75,000 units at $11.56) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- SEC Form 4 filed by Davis Aaron I.4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
- Large owner Third Rock Ventures Iv, L.P. sold $2,029,702 worth of shares (175,000 units at $11.60) (SEC Form 4)4 - Tango Therapeutics, Inc. (0001819133) (Issuer)